Lloyd C Trotman
Overview
Explore the profile of Lloyd C Trotman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
5123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Oni T, Biffi G, Baker L, Hao Y, Tonelli C, Somerville T, et al.
J Exp Med
. 2020 Jul;
217(9).
PMID: 32633781
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and new therapies are needed. Altered metabolism is a cancer vulnerability, and several metabolic pathways have been shown to promote PDAC. However,...
12.
Monje M, Borniger J, DSilva N, Deneen B, Dirks P, Fattahi F, et al.
Cell
. 2020 Apr;
181(2):219-222.
PMID: 32302564
Mounting evidence indicates that the nervous system plays a central role in cancer pathogenesis. In turn, cancers and cancer therapies can alter nervous system form and function. This Commentary seeks...
13.
Mathew G, Trotman L
J Exp Med
. 2020 Apr;
217(6).
PMID: 32236496
Prostate cancer is a slow-growing disease, but not always. A highly rare and lethal form of the disease shows survival rates of less than a year. It is called squamous...
14.
Lee M, Trotman L
Cold Spring Harb Perspect Med
. 2019 Dec;
10(10).
PMID: 31818848
The transduction of signals in the PTEN/PI3-kinase (PI3K) pathway is built around a phosphoinositide (PIP) lipid messenger, phosphatidylinositol trisphosphate, PI(3,4,5)P or PIP Another, more ancient role of this family of...
15.
Carbonetti G, Converso C, Clement T, Wang C, Trotman L, Ojima I, et al.
Prostate
. 2019 Oct;
80(1):88-98.
PMID: 31661167
Background: Prostate cancer (PCa) remains the second leading cause of cancer-related death among men. Taxanes, such as docetaxel and cabazitaxel are utilized in standard treatment regimens for chemotherapy naïve castration-resistant...
16.
Froeling F, Swamynathan M, Deschenes A, Chio I, Brosnan E, Yao M, et al.
Clin Cancer Res
. 2019 Sep;
25(23):7162-7174.
PMID: 31527169
Purpose: Napabucasin (2-acetylfuro-1,4-naphthoquinone or BBI-608) is a small molecule currently being clinically evaluated in various cancer types. It has mostly been recognized for its ability to inhibit STAT3 signaling. However,...
17.
Nowak D, Cohen Katsenelson K, Watrud K, Chen M, Mathew G, DAndrea V, et al.
J Cell Biol
. 2019 May;
218(6):1943-1957.
PMID: 31092557
Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the and tumor suppressor genes. In contrast, however, most candidate tumor suppressors are part of large recurrent hemizygous deletions, such...
18.
Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M, et al.
Science
. 2018 Sep;
361(6409).
PMID: 30262472
Cancer cells from a primary tumor can disseminate to other tissues, remaining dormant and clinically undetectable for many years. Little is known about the cues that cause these dormant cells...
19.
Naguib A, Mathew G, Reczek C, Watrud K, Ambrico A, Herzka T, et al.
Cell Rep
. 2018 Apr;
23(1):58-67.
PMID: 29617673
A hallmark of advanced prostate cancer (PC) is the concomitant loss of PTEN and p53 function. To selectively eliminate such cells, we screened cytotoxic compounds on Pten;Trp53 fibroblasts and their...
20.
Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, et al.
Cancer Res
. 2017 Nov;
78(2):348-358.
PMID: 29180472
A distinction between indolent and aggressive disease is a major challenge in diagnostics of prostate cancer. As genetic heterogeneity and complexity may influence clinical outcome, we have initiated studies on...